Short Interest in Nyxoah S.A. (NASDAQ:NYXH) Expands By 164.1%

Nyxoah S.A. (NASDAQ:NYXH - Get Free Report) was the target of a large growth in short interest in the month of March. As of March 31st, there was short interest totalling 168,200 shares, a growth of 164.1% from the March 15th total of 63,700 shares. Based on an average daily trading volume, of 106,100 shares, the days-to-cover ratio is presently 1.6 days. Approximately 1.1% of the company's shares are short sold.

Hedge Funds Weigh In On Nyxoah

Hedge funds have recently modified their holdings of the stock. Vestal Point Capital LP acquired a new position in Nyxoah during the fourth quarter valued at approximately $23,394,000. Renaissance Technologies LLC acquired a new stake in shares of Nyxoah in the 4th quarter valued at approximately $187,000. Kovack Advisors Inc. grew its stake in shares of Nyxoah by 100.0% in the fourth quarter. Kovack Advisors Inc. now owns 20,000 shares of the company's stock valued at $160,000 after buying an additional 10,000 shares in the last quarter. Geode Capital Management LLC increased its holdings in Nyxoah by 19.4% during the fourth quarter. Geode Capital Management LLC now owns 17,100 shares of the company's stock worth $137,000 after buying an additional 2,774 shares during the last quarter. Finally, Ameriprise Financial Inc. bought a new stake in Nyxoah during the fourth quarter worth $135,000.

Nyxoah Stock Up 0.2 %

Shares of Nyxoah stock traded up $0.01 during trading on Friday, reaching $6.03. The stock had a trading volume of 76,631 shares, compared to its average volume of 64,155. The company has a current ratio of 5.28, a quick ratio of 4.95 and a debt-to-equity ratio of 0.21. The company has a market capitalization of $205.38 million, a price-to-earnings ratio of -3.22 and a beta of 1.55. Nyxoah has a 52 week low of $5.55 and a 52 week high of $12.21. The stock has a fifty day moving average price of $8.85 and a two-hundred day moving average price of $9.07.

Nyxoah (NASDAQ:NYXH - Get Free Report) last issued its quarterly earnings results on Thursday, March 13th. The company reported ($0.49) earnings per share for the quarter, missing the consensus estimate of ($0.46) by ($0.03). The business had revenue of $1.35 million for the quarter, compared to the consensus estimate of $2.02 million. Nyxoah had a negative return on equity of 51.68% and a negative net margin of 1,043.93%. Sell-side analysts predict that Nyxoah will post -1.91 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

NYXH has been the subject of several recent analyst reports. HC Wainwright restated a "buy" rating and issued a $15.00 price target on shares of Nyxoah in a report on Tuesday, April 8th. Stifel Nicolaus decreased their price objective on Nyxoah from $16.00 to $15.00 and set a "buy" rating for the company in a research report on Friday, March 14th.

Nyxoah Company Profile

Nyxoah SA, a medical technology company, focuses on the development and commercialization of solutions to treat sleep disordered breathing conditions. The company's lead solution comprises Genio system, a CE-Marked, patient-centric, and hypoglossal neurostimulation therapy to treat moderate to severe obstructive sleep apnea.